ACHV shows severe cash burn acceleration with operating cash flow worsening 66% to -$49.5M while R&D expenses surged 44% and net losses deepened 37% to -$54.6M.
The dramatic deterioration in cash burn rate signals unsustainable financial trajectory for this single-product biotech company. Despite improved cash position likely from equity financing, the accelerating losses and mounting liabilities create material going concern risks, especially given their exclusive dependence on cytisinicline with no guarantee of FDA approval.
ACHV's financials reveal a company burning cash at an alarming and accelerating pace, with operating cash flow deteriorating 66% to -$49.5M and R&D expenses jumping 44% to $22.8M, driving net losses 37% deeper to -$54.6M. While cash increased 64% to $20.9M (likely from equity raises evidenced by the 53% share count increase), this improvement is overshadowed by rising liabilities and dramatically higher interest expense (+59.5%). The overall picture signals a biotech in financial distress with unsustainable burn rates that could quickly exhaust available capital.
Capex reduced 85.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 66.2% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash position surged 64.1% — strong cash generation or capital raise providing significant financial cushion.
Interest expense surged 59.5% — significant debt increase or rising rates materially impacting earnings.
R&D investment increased 44.3% — signals commitment to future product development, though near-term margin impact.
Net income declined 37.2% — review whether driven by operations, interest costs, or non-recurring items.
Current liabilities surged 35.9% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities increased 14.3% — monitor debt-to-equity ratio and interest coverage.
Receivables grew 14.3% — monitor days sales outstanding for collection efficiency.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →